Interaction reference

GLP-1 receptor agonists with Sulfonylureas

Sulfonylureas force the pancreas to release insulin regardless of blood glucose. Adding a GLP-1 stacks two hypoglycemia mechanisms.

Hypoglycemia is the central concern — most prescribers reduce the sulfonylurea dose by half or stop it.

Also known as: Glipizide, Glyburide, Glimepiride, Amaryl

Per-GLP-1 breakdown

Wegovysemaglutide 2.4 mg
Major
Mechanism: Sulfonylurea-induced insulin release is glucose-independent; GLP-1 effects stack on top, raising hypoglycemia frequency.
What to do: Most clinicians cut the sulfonylurea dose by 50% at GLP-1 initiation, then re-evaluate at 4-8 weeks. Many discontinue the sulfonylurea entirely once GLP-1 maintenance dose is reached.
Zepboundtirzepatide
Major
Mechanism: Sulfonylurea-induced insulin release is glucose-independent; GLP-1 effects stack on top, raising hypoglycemia frequency.
What to do: Most clinicians cut the sulfonylurea dose by 50% at GLP-1 initiation, then re-evaluate at 4-8 weeks. Many discontinue the sulfonylurea entirely once GLP-1 maintenance dose is reached.
Ozempicsemaglutide
Major
Mechanism: Sulfonylurea-induced insulin release is glucose-independent; GLP-1 effects stack on top, raising hypoglycemia frequency.
What to do: Most clinicians cut the sulfonylurea dose by 50% at GLP-1 initiation, then re-evaluate at 4-8 weeks. Many discontinue the sulfonylurea entirely once GLP-1 maintenance dose is reached.
Mounjarotirzepatide
Major
Mechanism: Sulfonylurea-induced insulin release is glucose-independent; GLP-1 effects stack on top, raising hypoglycemia frequency.
What to do: Most clinicians cut the sulfonylurea dose by 50% at GLP-1 initiation, then re-evaluate at 4-8 weeks. Many discontinue the sulfonylurea entirely once GLP-1 maintenance dose is reached.
Foundayoorforglipron
Major
Mechanism: Sulfonylurea-induced insulin release is glucose-independent; GLP-1 effects stack on top, raising hypoglycemia frequency.
What to do: Most clinicians cut the sulfonylurea dose by 50% at GLP-1 initiation, then re-evaluate at 4-8 weeks. Many discontinue the sulfonylurea entirely once GLP-1 maintenance dose is reached.

Sources

ADA Standards of Care 2024 (opens in a new tab) — American Diabetes Association

See other interactions

Full interaction index